{"analyses":[{"ciLowerLimit":"0.562","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.911","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0063","paramType":"Hazard Ratio (HR)","paramValue":"0.715","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.9","upperLimit":"3.9","value":"3.1"},{"groupId":"OG001","lowerLimit":"3.5","upperLimit":"4.2","value":"4.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"155"},{"groupId":"OG001","value":"149"}],"units":"Participants"}],"description":"DOR is defined as the time interval from first occurrence of a documented objective response to the time of disease progression as determined by the investigator using RECIST v1.1 or death from any cause, whichever comes first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received intravenous infusions of placebo in combination with carboplatin to achieve an initial target AUC of 5 mg/mL/min followed by etoposide 100 mg/m\\^2 on Day 1 of every 21-day cycle during the induction phase (Cycles 1-4). On Days 2 and 3 of every 21-day cycle during the induction phase (Cycles 1-4), etoposide 100 mg/m\\^2 was administered alone. Thereafter, participants received maintenance (Cycle 5 onward) placebo on Day 1 of every 21-day cycle until persistent radiographic PD, symptomatic deterioration, intolerable toxicity, withdrawal of consent, death, or study termination by the Sponsor.","id":"OG000","title":"Placebo + Carboplatin + Etoposide"},{"description":"Participants received intravenous infusions of atezolizumab 1200 milligrams (mg) in combination with carboplatin to achieve an initial target area under the concentration-time curve (AUC) of 5 milligrams per milliliter per minute (mg/mL/min) followed by etoposide 100 milligrams per square meter (mg/m\\^2) on Day 1 of every 21-day cycle during the induction phase (Cycles 1-4). On Days 2 and 3 of every 21-day cycle during the induction phase (Cycles 1-4), etoposide 100 mg/m\\^2 was administered alone. Thereafter, participants received maintenance (Cycle 5 onward) atezolizumab 1200 mg on Day 1 of every 21-day cycle until persistent radiographic PD, symptomatic deterioration, intolerable toxicity, withdrawal of consent, death, or study termination by the Sponsor.","id":"OG001","title":"Atezolizumab + Carboplatin + Etoposide"}],"paramType":"MEDIAN","populationDescription":"The ITT population was defined as all randomized participants, regardless of whether the participant received the assigned treatment.","reportingStatus":"POSTED","timeFrame":"First occurrence of PR or CR until PD or death, whichever occurs first (up to approximately 23 months)","title":"Duration of Response (DOR) as Assessed by the Investigator Using RECIST v1.1 in the Global Population","type":"SECONDARY","unitOfMeasure":"Months"}